
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics reported a net loss of $1.14 per share for the second quarter of 2025, which is an improvement over the company's earlier estimate of a $1.22 per share loss. This narrower loss indicates a potentially strong financial management and execution in their clinical research segment. Additionally, the favorable safety profile of their lead candidate, OKI-219, which demonstrated no severe adverse events and high tolerability, underscores the promising therapeutic potential of the company's precision medicine approach in treating underserved cancers.
Bears say
OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share in 2025, a slight improvement from the previous estimate of $4.75 per share, which indicates ongoing financial challenges. The company's negative outlook is significantly influenced by potential risks, including negative clinical results from its lead asset, OKI-219, and delays in advancing its pipeline candidates, which could hinder future revenues. Additionally, uncertainties surrounding regulatory approvals, competition from other therapies, and the risk of long-term dilution further exacerbate concerns regarding the company's financial viability.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares